Navigation Links
Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Date:9/19/2007

eases. In preclinical studies, REP3123 has been show to inhibit growth, toxin production and spore-forming in C. difficile bacteria. Replidyne is also pursuing the development of other novel anti-infective programs based on its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at http://www.sec.gov. Al
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... announces the appointment of Jarrod Longcor ... Longcor is responsible for structuring, negotiating and executing ... as well as providing management and strategic leadership ... the Executive leadership team. Mr Longcor ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... 22, 2014 Avanir Pharmaceuticals, Inc. (NASDAQ: ... to sell $200 million of its common stock in ... and BofA Merrill Lynch are acting as joint book-running ... a 30-day option to purchase additional shares of its ... in the offering are being sold by Avanir.  The ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... , ... a new market research report is available in ... - A US Market Review , ... medical adhesives and sealants is gaining preeminence in ...
... Cyberonics, Inc. (Nasdaq: CYBX ) today announced that Dan ... Officer, will present at the 21st Annual Piper Jaffray Health Care ... PM EST. The conference session and webcast will be audio ... will host a webcast of the presentation live and by replay ...
Cached Medicine Technology:Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2
(Date:9/23/2014)... has awarded $10.1 million in supplemental funding to bolster ... of sex in preclinical and clinical studies. , This ... is a catalyst for considering sex as a fundamental ... in preclinical research can obscure key findings related to ... approach will result in greater awareness of the need ...
(Date:9/23/2014)... The Westlake Village sedation dentist ... oral sedation with treatment for new patients. Studies have ... dental anxiety or dental phobia. These common conditions are ... keep patients from seeking desperately needed dental care. , ... and surrounding areas now have an opportunity to manage ...
(Date:9/23/2014)... September 23, 2014 Kenall Manufacturing, ... expanded its MedMaster™ M4 product line with a ... the M4 product line – currently available with ... – providing more flexibility when designing lighting for ... MedMaster M4 Series include:, •Three sizes available ...
(Date:9/23/2014)... 23, 2014 Catalent Pharma ... delivery technologies and development solutions for drugs, ... that it had reached an exclusive development ... company, Cingulate Therapeutics (CTx), to support the ... pharmaceutical products for the treatment of Attention ...
(Date:9/23/2014)... losing your job can increase the risk for developing asthma, ... more than 7,000 employed adults in Germany. Between 2009 and ... questions about the respiratory disorder and also on whether they ... More than 100 new cases of asthma were diagnosed among ... study period. The researchers noted that for every 25 ...
Breaking Medicine News(10 mins):Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3Health News:Job Worries Can Raise Asthma Risk, Study Says 2
... Alberta - A University of Alberta researcher in collaboration ... really does come with age, at least when it ... Dr. Florin Dolcos, assistant professor of psychiatry and neuroscience ... patterns that help healthy older people regulate and control ...
... 12 Not so long ago, any mention ... images of third-world,children with rickets and bone deformities. ... world to the developed, where Vitamin D deficiency,among ... rising to,astronomical proportions -- by some estimates, affecting ...
... Would Have Improved Benefits for Prevention, Mental,Health ... HARRISBURG, Pa., June 12 SUMMARY: ... critical legislation to protect and,improve Medicare for ... it. The,Medicare Improvements for Patients and Providers ...
... Serve Elective Cash Pay ... Patients, ... services for elective (cash pay) surgery, today,announced a leap forward in its ... bariatric surgeons, cash pay business.,Beginning July 1st, 2008, the BLISCare(SM) insurance policy ...
... complaints of insomnia predicted a healthier life, study finds ... is associated with healthy aging, a new study found. ... assessed 2,226 women aged 60 and older for use ... awakening, snoring, overall sleep quality, and sleep duration. Based ...
... MEDRAD, INC., has signed a,distribution and ... owned subsidiary of Siemens Medical Solutions USA, ... to inject Fluorodeoxyglucose,(FDG) for Positron Emission Tomography/Computed ... way. The partnership will leverage,MEDRAD,s soon to ...
Cached Medicine News:Health News:New research shows how aging brain brings a healthy dose of perspective 2Health News:Spotting Vitamin-D Deficiency in the Absence of Symptoms: ZRT Laboratory's New, One-of-a-Kind Blood Spot Test Answers the Call for Early Detection of Rapidly Rising D-Deficiencies 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 2Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 3Health News:Better Sleepers Are 'Successful Agers' 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
CataRhex PRO the portable cataract extraction system with automated capsulotomy....
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Medicine Products: